Tobacco dependence & smoking cessation
treatable addiction · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Tobacco dependence is a chronic relapsing condition and the leading modifiable cause of respiratory disease. Combining behavioural support with pharmacotherapy substantially increases quit rates; every healthcare contact is an opportunity to intervene.
Red flags
- Severe depression or suicidal ideation during cessation
- Unstable cardiovascular disease (time pharmacotherapy appropriately)
- Pregnancy (prefer behavioural support +/- NRT under guidance)
- Seizure history (caution with bupropion)
Assessment
Differential diagnosis
- Nicotine dependence (cigarettes)
- Dual use with vaping/e-cigarettes
- Smokeless tobacco use
- Cannabis co-use
- Coexisting mental-health/substance disorder affecting cessation
Investigations
- Smoking history and dependence assessment (e.g. time to first cigarette)
- Exhaled carbon monoxide measurement
- Assessment of comorbidities and mental health
- Medication review for interactions (smoking induces some drug metabolism)
- Readiness and prior quit-attempt history
Management
- Ask about tobacco use at every contact and document it
- Advise quitting clearly and personalise the respiratory health benefits
- Assess dependence, readiness to quit and prior attempts
- Offer behavioural support / referral to a stop-smoking service (very brief advice at minimum)
- Offer pharmacotherapy to all dependent smokers wishing to quit
- Set a quit date and combine behavioural support with medication
- Consider combination nicotine replacement (patch plus short-acting) for higher dependence
- Discuss e-cigarettes as a harm-reduction aid for those who cannot quit with licensed therapy
- Review drug doses affected by stopping smoking (e.g. theophylline, clozapine, warfarin)
- Arrange follow-up, relapse prevention and re-treatment of relapses without judgement
Drugs & doses
Nicotine replacement: patch 21 mg/24 h plus a short-acting form (gum 2-4 mg / lozenge / inhalator) as needed
Varenicline 0.5 mg PO daily titrated to 1 mg twice daily (start 1-2 weeks before quit date, 12 weeks)
Bupropion 150 mg PO daily for 3 days then twice daily (start before quit date)
Cytisine where available as an alternative course
Disposition
Stop-smoking service referral; integrate into every respiratory encounter; proactive relapse follow-up.
Complications & pitfalls
- Relapse
- Nicotine-withdrawal symptoms (irritability, craving, low mood)
- Weight gain
- Drug-level changes on stopping smoking (e.g. clozapine, theophylline toxicity)
Exam pearls
- Combining a nicotine patch with a fast-acting form outperforms single-agent NRT
- Smoking cessation is the only intervention proven to alter the natural history of COPD
- Stopping smoking reduces clearance of clozapine and theophylline — monitor levels/doses
- Relapse is part of the process; re-offer treatment rather than withdraw support
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.